TY  - JOUR

T1  - Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

JO  - The Lancet Haematology

UR  - https://eprints.whiterose.ac.uk/id/eprint/217236

PY  - 2024/09/06

AU  - Cook G

AU  - Ashcroft AJ

AU  - Senior E

AU  - Olivier C

AU  - Hockaday A

AU  - Richards J

AU  - Cavenagh JD

AU  - Snowden JA

AU  - Drayson MT

AU  - de Tute R

AU  - Roberts L et al

ED  - 

DO  - DOI: 10.1016/s2352-3026(24)00249-7

PB  - Elsevier BV

VL  - 11

IS  - 11

SP  - e816

EP  - e829

Y2  - 2025/11/15

ER  -